Company news

Veracyte, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

June 19, 2023

Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023

June 11, 2023

New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer

May 24, 2023

New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

May 23, 2023

Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer

May 11, 2023

Veracyte Announces First Quarter 2023 Financial Results

May 3, 2023

New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules

May 3, 2023

Veracyte Announces Release of Inaugural ESG Report

May 2, 2023

New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients

May 2, 2023

Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer

May 1, 2023

Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference

April 30, 2023

Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier

April 28, 2023

Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting

April 26, 2023

New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification

April 16, 2023

Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023

April 12, 2023

Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting

April 11, 2023

Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners

March 14, 2023

Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank

March 10, 2023

Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results

February 21, 2023

Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer

February 14, 2023

New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment

February 12, 2023

Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023

February 5, 2023

Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules

January 31, 2023

Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium

January 31, 2023

Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis

December 14, 2022

Veracyte Announces Third Quarter 2022 Financial Results

November 1, 2022

Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting

October 31, 2022

Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference

October 26, 2022

New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

October 24, 2022

Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer

October 23, 2022

New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

October 17, 2022

Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022

October 12, 2022

New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men

September 21, 2022

Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access

September 12, 2022

New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer

September 10, 2022

New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy

September 6, 2022

Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

August 31, 2022

Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022

August 30, 2022

Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors

August 10, 2022

Veracyte Announces Second Quarter 2022 Financial Results

August 1, 2022

Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid

July 19, 2022

Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022

July 13, 2022

New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis

July 12, 2022

Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year

June 26, 2022

New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice

June 19, 2022

Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression

June 2, 2022

Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer

May 30, 2022

Veracyte to Present at Upcoming Investor Conferences

May 25, 2022

Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors

May 25, 2022

New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier

May 25, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 19 decks. Every deck is listed under its year.